Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomized clinical trial

Diabetes Care

Volumn 39, Issue 2, 2016, Pages 222-230

  Davies, Melanie J ^a   Bain, Stephen C ^b   Atkin, Stephen L ^c   Rossing, Peter ^d   Scott, David ^e   Shamkhalova, Minara S ^f   Bosch Traberg, Heidrun ^g   Syrén, Annika ^g   Umpierrez, Guillermo E ^h  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^d STENO DIABETES CENTER   (Denmark)

^e Clinical Research Development Associates   (United States)

^f ENDOCRINOLOGY RESEARCH CENTRE   (Russian Federation)

^g NOVO NORDISK A S   (Denmark)

^h EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; AMYLASE; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; METFORMIN PLUS PIOGLITAZONE; PIOGLITAZONE; PLACEBO; REPAGLINIDE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL LIPASE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MODERATE RENAL IMPAIRMENT; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; ADOLESCENT; BODY WEIGHT; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; GASTROINTESTINAL TRACT; MIDDLE AGED; MULTICENTER STUDY;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL TRACT; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; RENAL INSUFFICIENCY;

EID: 84962052167     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2883     Document Type: Article

References (38)

1. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013;3:1-163
2. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2013 Annual Data Report. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013
3. Reutens AT. Epidemiology of diabetic kidney disease. Med Clin North Am 2013;97:1-18
4. Avogaro A, Schernthaner G. Achieving gly-cemic control in patients with type 2 diabetes and renal impairment. Acta Diabetol 2013;50: 283-291
5. Herrington WG, Nye HJ, Aung T. Metformin use in chronic kidney disease: new evidence to guide dosing. QJM 2013;106:1059-1061
6. Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-555
7. Schweizer A, Dejager S. Experience with vilda-gliptin in patients $75 years with type 2 diabetes and moderate or severe renal impairment. Diabetes Ther 2013;4:257-267
8. McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013;36:237-244
9. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagli-flozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014;85:962-971
10. Krepinsky J, Ingram AJ,Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 2000;35:500-505
11. Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia 1984;27:351-357
12. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001;161:1653-1659
13. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43:1664-1669
14. Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglu-tide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 2010;38:1944-1953
15. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009;68:898-905
16. Davidson JA, Brett J, Falahati A, Scott D. Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract 2011;17:345-355
17. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 59th WMA General Assembly, Seoul. 1 October 2008.
18. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice, 01 May 1996
19. Levey AS, Coresh J, Greene T, et al.; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254
20. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28: 1245-1249
21. Scott D, Umpierrez G, Atkin S, et al. Efficacy and safety of liraglutide versus placebo by eGFR subgroup in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized trial (Abstract). J Am Soc Nephrol 2014;25:75A
22. Giorda CB, Nada E, Tartaglino B. Pharmaco-kinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine 2014;46:406-419
23. Leiter LA, Carr MC, Stewart M, et al. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care 2014;37:2723-2730
24. Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 2006;7:367-374
25. Dicembrini I, Bigiarini M, Mannucci E. Lixisenatide: clinical profile and available evidence. Diabetes Manage 2014;4:71-84
26. Davies MJ, Kela R, Khunti K. Liraglutide-overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab 2011;13:207-220
27. Marre M, Shaw J, Brändle M, et al.; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-278
28. Nauck M, Frid A, Hermansen K, et al.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009;32:84-90
29. Garber A, Henry R, Ratner R, et al.; LEAD-3 (Mono) Study Group. Liraglutide versus glime-piride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-481
30. Zinman B, Gerich J, Buse JB, et al.; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidine-dione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-1230
31. Russell-Jones D, Vaag A, Schmitz O, et al.; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52: 2046-2055
32. Buse JB, Rosenstock J, Sesti G, et al.; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374:39-47
33. Gerstein HC, Mann JF, Yi Q, et al.; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-426
34. Schmieder RE, Mann JF, Schumacher H, et al.; ONTARGET Investigators. Changes in albuminuria predict mortality and morbidity in patientswith vascular disease. J Am Soc Nephrol 2011;22:1353-1364
35. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009;4: 1121-1127
36. Steinberg W, DeVries JH, Wadden TA, Jensen CB, Svendsen CB, Rosenstock. Tu1502 longitudinal monitoring of lipase and amylase in adults with type 2 diabetes and obesity: evidence from two phase 3 randomized clinical trials with the once-daily GLP-1 analog liraglu-tide. Gastroenterology 2012;142:S850-S851
37. Steinberg WM, Nauck MA, Zinman B, et al.; LEADER Trial investigators. LEADER 3-lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. Pancreas 2014;43:1223-1231
38. Lando HM, Alattar M, Dua AP. Elevated amylase and lipase levels in patients using gluca-gonlike peptide-1 receptor agonists ordipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract 2012;18:472-477